PF-07868489 Open-Label Extension in Pulmonary Arterial Hypertension

Phase 2, open-label, single-arm trial of PF-07868489 in pulmonary arterial hypertension (PAH), sponsored by Pfizer. Primary endpoints: Number of Participants with Treatment Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs) at 111 weeks, Number of Participants With Change From Baseline in Laboratory Tests Results at 111 weeks and 1 more. Started Nov 2025; status: terminated.